Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial

Tao Ma, Xueli Bai, Qichun Wei, Yongjie Shui, Mengyi Lao, Wen Chen, Bingfeng Huang, Risheng Que, Shunliang Gao, Yun Zhang, Wei Chen, Ji Wang, Tingbo Liang, Tao Ma, Xueli Bai, Qichun Wei, Yongjie Shui, Mengyi Lao, Wen Chen, Bingfeng Huang, Risheng Que, Shunliang Gao, Yun Zhang, Wei Chen, Ji Wang, Tingbo Liang

Abstract

Background: The role of adjuvant radiation in pancreatic adenocarcinoma (PDAC) remains unclear. We aimed to investigate the efficacy of gemcitabine combined with stereotactic body radiation therapy (SBRT) as adjuvant therapy for resected stage II PDAC.

Methods: In this single-center randomized controlled trial, patients with stage II PDAC that underwent margin-negative resection were randomly assigned to gemcitabine-alone adjuvant chemotherapy or adjuvant SBRT followed by gemcitabine chemotherapy. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included locoregional recurrence-free survival (LRFS), overall survival (OS), and incidence of adverse events.

Results: Forty patients were randomly assigned to treatment between Sep 1, 2015 and Mar 31, 2018. Of these, 38 were included in the intention-to-treat analysis (20 in gemcitabine arm and 18 in gemcitabine plus SBRT arm). The median RFS and OS were 9.70, 28.0 months in the gemcitabine arm and 5.30, 15.0 months in the gemcitabine plus SBRT arm (RFS, P = 0.53; OS, P = 0.20), respectively. The median LRFS in both arms was unreached (P = 0.81). Grade 3 or 4 adverse events were all comparable between the two arms. Evaluation of data from the enrolled patients indicated that the addition of adjuvant SBRT was not associated with either better local disease control or recurrence-free survival.

Conclusions: Adjuvant SBRT neither provided a survival benefit nor improved local disease control in resected stage II PDAC.

Trial registration: ClinicalTrials.gov, NCT02461836 . Registered 03/06/2015.

Keywords: Adjuvant therapy; Gemcitabine; Pancreatic adenocarcinoma; Randomized controlled trial; SBRT.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
The CONSORT flow diagram for this trial
Fig. 2
Fig. 2
Recurrence-free survival (RFS) (a), locoregional recurrence-free survival (LRFS) (c), and overall survival (OS) (e) of the whole cohort; and RFS (b), LRFS (d), and OS (f) of node-positive patients

References

    1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210. doi: 10.1056/NEJMoa032295.
    1. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277. doi: 10.1001/jama.297.3.267.
    1. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024. doi: 10.1016/S0140-6736(16)32409-6.
    1. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903. doi: 10.1001/archsurg.1985.01390320023003.
    1. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase iii trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–782. doi: 10.1097/00000658-199912000-00006.
    1. Rubio C, Morera R, Hernando O, Leroy T, Lartigau SE. Extracranial stereotactic body radiotherapy. Review of main SBRT features and indications in primary tumors. Rep Pract Oncol Radiother. 2013;18:387–96. doi: 10.1016/j.rpor.2013.09.009.
    1. Kim SK, Wu CC, Horowitz DP. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. J Gastrointest Oncol. 2016;7:479–486. doi: 10.21037/jgo.2015.10.01.
    1. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86:516–522. doi: 10.1016/j.ijrobp.2013.02.022.
    1. Comito T, Cozzi L, Zerbi A, Franzese C, Clerici E, Tozzi A, et al. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: a retrospective study. Eur J Surg Oncol. 2017;43:735–742. doi: 10.1016/j.ejso.2016.12.012.
    1. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121:1128–1137. doi: 10.1002/cncr.29161.
    1. Yu W, Hu W, Shui Y, Zhu X, Li C, Ren X, et al. Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. Radiat Oncol. 2016;11:138. doi: 10.1186/s13014-016-0714-7.
    1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. Seven. New York: Springer; 2010.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55. doi: 10.1097/00000421-198212000-00014.
    1. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:2541–2556. doi: 10.1200/JCO.2016.67.5553.
    1. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56–68. doi: 10.1093/annonc/mdv295.
    1. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GER - COR phase II study. J Clin Oncol. 2010;28:4450–4456. doi: 10.1200/JCO.2010.30.3446.
    1. Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, Nathan H. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: a propensity-matched national cancer database (NCDB) analysis. Ann Surg. 2021;273:587–594. doi: 10.1097/SLA.0000000000003242.
    1. Morganti AG, Cellini F, Buwenge M, Arcelli A, Alfieri S, Calvo FA, et al. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer. 2019;19:569. doi: 10.1186/s12885-019-5790-2.
    1. Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Carpenter DH, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;47:753–760. doi: 10.1001/archsurg.2012.1126.
    1. McDonald AM, Dulaney CR, López-Araujo J, Posey JA, Keene KS, Christein JD, et al. Patterns of failure for lymph node-positive resected pancreatic adenocarcinoma after adjuvant radiotherapy or gemcitabine-based chemotherapy alone. J Gastrointest Cancer. 2015;46:149–155. doi: 10.1007/s12029-015-9702-7.
    1. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–3510. doi: 10.1200/JCO.2007.15.8469.
    1. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005) J Clin Oncol. 2008;26:3511–3516. doi: 10.1200/JCO.2007.15.8782.
    1. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–1585. doi: 10.1016/S0140-6736(01)06651-X.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa